Dr. Reddy's Laboratories Ltd Common Stock vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Dr. Reddy's Laboratories Ltd Common Stock trades at $12.75 (market cap $10.78B), while iShares 1 3 Year Treasury Bond ETF trades at $81.3 (market cap $26.87B). The key difference: iShares 1 3 Year Treasury Bond ETF is far larger — about 2.5× Dr. Reddy's Laboratories Ltd Common Stock's market cap, and Dr. Reddy's Laboratories Ltd Common Stock pays a 0.65% dividend while iShares 1 3 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dr. Reddy's Laboratories Ltd Common Stock for 0 Days and iShares 1 3 Year Treasury Bond ETF for 64 Days on average.
| RDY | SHY | |
|---|---|---|
Market Cap | $10.78B | $26.87B |
Volume | 2,724,343 | 3,180,822 |
Sector | Health | Fixed Income |
52-Week High | $15.38 | $83.18 |
52-Week Low | $11.38 | $81.05 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $10.68B | — |
Dividend Yield | 0.65% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SHY, a US stock, trades at $81.19 with minimal daily movement, reflecting stability amid broader bond market volatility. Technical indicators show a bearish trend with moving averages signaling caution, while oscillators remain neutral. Recent dividend actions provide income, but key financial ratios are unavailable. The stock's price action is tightly range-bound with support and resistance near $81.
The outlook for SHY is cautious due to bearish technical signals and a lack of fundamental data. Risks include interest rate sensitivity and macroeconomic pressures from rising bond yields. Investment opportunities may lie in its dividend yield if fundamentals strengthen, but current sentiment and technicals suggest limited near-term upside.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Dr. Reddy's Laboratories Ltd. develops and manufactures generic medicines, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter (OTC) products, headquartered in Hyderabad, India, with therapeutic focus areas spanning gastrointestinal, cardiovascular, oncology, and dermatology.
Read more on RDY →SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →